Loading...
XSHG
603858
Market cap2.43bUSD
Jun 16, Last price  
16.41CNY
1D
-0.85%
1Q
7.40%
Jan 2017
-77.61%
IPO
-75.90%
Name

Shandong Buchang Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
54.59
P/S
1.31
EPS
0.30
Div Yield, %
0.77%
Shrs. gr., 5y
-0.63%
Rev. gr., 5y
-0.62%
Revenues
13.25b
-11.41%
5,871,833,2507,036,593,8278,591,698,81310,333,616,10211,655,627,38712,320,883,10113,863,918,66113,664,752,61314,255,454,95916,006,714,33915,762,679,80214,951,252,69413,245,133,302
Net income
319m
1,228,166,4911,251,331,2991,168,574,7541,323,627,3003,536,764,3641,769,364,6461,637,952,3171,888,405,3721,945,997,1731,860,894,3351,162,117,9190318,973,324
CFO
-164m
L
01,349,185,8551,113,956,7901,780,581,7632,120,730,7161,668,783,0821,961,975,6032,050,837,3142,621,333,5281,958,763,3871,320,513,3692,755,627,692-164,259,736
Dividend
Aug 20, 20240.126 CNY/sh

Profile

Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China. Shandong Buchang Pharmaceuticals Co., Ltd. was a former subsidiary of Shanghai Zhangjiang (Group) Co., Ltd.
URL
http://www.buchang.com/
IPO date
Nov 18, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
13,245,133
-11.41%
14,951,253
-5.15%
Cost of revenue
11,277,296
12,242,528
Unusual Expense (Income)
NOPBT
1,967,837
2,708,725
NOPBT Margin
14.86%
18.12%
Operating Taxes
242,692
331,594
Tax Rate
12.33%
12.24%
NOPAT
1,725,146
2,377,131
Net income
318,973
 
Dividends
(1,194,264)
(398,175)
Dividend yield
6.35%
1.71%
Proceeds from repurchase of equity
(9,990)
BB yield
0.05%
Debt
Debt current
240,117
999,492
Long-term debt
2,263,954
2,179,850
Deferred revenue
2
330,554
Other long-term liabilities
148,066
144,000
Net debt
(272,079)
(418,028)
Cash flow
Cash from operating activities
(164,260)
2,755,628
CAPEX
(529,915)
Cash from investing activities
(195,058)
Cash from financing activities
(1,069,676)
FCF
1,388,447
2,932,337
Balance
Cash
1,048,223
2,875,140
Long term investments
1,727,926
722,230
Excess cash
2,113,893
2,849,808
Stockholders' equity
8,313,824
9,868,725
Invested Capital
12,071,956
12,766,519
ROIC
13.89%
16.46%
ROCE
13.78%
17.25%
EV
Common stock shares outstanding
1,106,010
1,106,043
Price
17.01
-19.04%
21.01
-0.38%
Market cap
18,813,232
-19.04%
23,237,956
-0.38%
EV
18,300,169
22,819,928
EBITDA
2,560,412
3,206,288
EV/EBITDA
7.15
7.12
Interest
109,931
135,100
Interest/NOPBT
5.59%
4.99%